HeartBeam, Inc. filings document material events for a Nasdaq-listed medical technology issuer with common stock under BEAT and warrants under BEATW. Its 8-K disclosures cover underwriting agreements and common-stock offering terms, emerging growth company status, and FDA-related correspondence for its 12-Lead ECG Synthesis Software.
These records also identify capital-structure changes and formal event disclosures tied to commercialization and regulatory development of HeartBeam's 3D ECG technology.
HeartBeam, Inc. granted director Willem Elfrink 93,750 restricted stock units and options to buy 93,750 common shares on October 2, 2026. Each RSU represents a contingent right to one common share; the RSUs vest in full on the earlier of October 2, 2027 or the next annual meeting of stockholders following the grant date, subject to continued service. Half the options vest on the grant date and half on January 1, 2027, subject to continued service. The options have a $0.435 exercise price, expire October 2, 2036, and unvested options accelerate immediately before a Change in Control.
HeartBeam, Inc. director Richard Ferrari received two restricted stock unit awards on October 2, 2026: 125,000 annual RSUs and 90,625 special RSUs, plus an option covering 125,000 shares at an exercise price of $0.435 per share. The option was granted for his additional responsibilities as Chair of the Board; the reported post-grant position was 125,000 shares subject to the option, which expires October 2, 2036.
The annual RSUs vest in full on the earlier of October 2, 2027 or the issuer’s next annual meeting of stockholders after the grant, subject to continued service as a non-employee director. Half of the special RSUs vested on the grant date, with the rest scheduled to vest January 1, 2027 subject to continued service; unvested RSUs vest in full immediately before a Change in Control if service continues through that date. The option vests in monthly installments, subject to continued service, and will be fully vested on July 1, 2027.
HeartBeam, Inc. reported that director Michael R. Jaff received two restricted stock unit (RSU) awards on October 2, 2026: 93,750 RSUs as an annual non-employee director award and 37,500 RSUs as a special award connected to suspension of cash retainers from July 1 through December 31, 2026. Each RSU represents a contingent right to one common share upon vesting. The annual award vests on the earlier of October 2, 2027, or the next annual meeting, subject to continued service. Half of the special award vested on the grant date; the remainder vests January 1, 2027, subject to continued service. Unvested units under the special award vest in full immediately before a Change in Control, subject to continued service.
HeartBeam, Inc. director Marga Ortigas-Wedekind received 93,750 restricted stock units (RSUs) on October 2, 2026; each RSU represents a contingent right to one common share upon vesting. All RSUs vest on the earlier of October 2, 2027 or the next annual meeting after the grant, subject to continued service as a non-employee director. She also received options for 81,250 common shares at a $0.435 exercise price, expiring October 2, 2036. Half vest on the grant date and half on January 1, 2027, subject to continued service; any then-unvested shares fully accelerate immediately before a Change in Control.
HeartBeam, Inc.'s non-employee director Kenneth Warwick Nelson III was granted two direct restricted stock unit (RSU) awards on October 2, 2026: 93,750 RSUs as an annual award and 31,250 RSUs as a special award. Each RSU represents a contingent right to receive one share of common stock upon settlement.
The annual award vests in full on the earlier of October 2, 2027 or the next annual meeting after the grant, subject to continued service. The special award was granted in connection with suspended cash retainers for July 1 through December 31, 2026; half vested on the grant date and the remaining RSUs will vest January 1, 2027, subject to continued service. Unvested special-award RSUs vest in full immediately before a Change in Control, subject to continued service.
HeartBeam, Inc. (BEAT) non-employee director George de Urioste received 93,750 restricted stock units and a stock option covering 93,750 common shares on October 2, 2026. The option has a $0.435 per-share exercise price and expires October 2, 2036. The RSUs vest in full on the earlier of October 2, 2027 or the date of the next annual meeting following the grant date, subject to continued service as a non-employee director. Half of the option shares vest on the grant date and the remaining half on January 1, 2027, subject to continued service through the applicable vesting dates; any then-unvested shares accelerate immediately prior to a Change in Control, as defined in the Plan.
HeartBeam, Inc. entered into an At-The-Market Equity Offering Sales Agreement with Titan Partners Securities LLC as sales agent. Under this agreement, HeartBeam may sell from time to time up to $25,000,000 of common stock through at-the-market offerings under its existing shelf Registration Statement on Form S-3. The company filed a prospectus supplement dated August 14, 2026 covering these sales. Titan Partners will receive a commission of up to 3% of the gross sales price per share and has been provided customary indemnification and contribution rights.
HeartBeam, Inc. is launching an “at‑the‑market” equity program to sell up to $25,000,000 of common stock from time to time through Titan Partners Securities as sales agent. Titan will receive a cash commission of 3.0% of gross proceeds and may be deemed an underwriter.
The company’s common stock trades on Nasdaq under “BEAT”; the last reported price on August 13, 2026 was $0.5898 per share, implying up to about 42.4 million shares if fully utilized at that price, compared with 56,349,171 shares outstanding before this offering. Net proceeds are intended for working capital and general corporate purposes, with management retaining broad discretion over deployment.
HeartBeam is a pre‑revenue medical technology company focused on ambulatory, cable‑free, synthesized 12‑lead ECG solutions, supported by a growing international patent portfolio and recent FDA clearances. Independent auditors’ reports for 2024 and 2025 included explanatory paragraphs raising substantial doubt about the company’s ability to continue as a going concern, and the filing highlights dilution and share‑price pressure risks from this ATM program.
HeartBeam, Inc. (BEAT) has an amended Schedule 13D filing from Mark E. Strome and affiliated entities regarding holdings of its common stock. Strome Mezzanine Fund II, LP purchased 750,000 shares in HeartBeam’s underwritten public offering of 12,500,000 shares at $0.80 per share, for a total of $600,000, funded with its own capital.
Following this and other positions, Mark E. Strome reports beneficial ownership of 3,764,200 shares, or 6.8% of HeartBeam’s common stock, based on 55,506,835 shares outstanding as of May 11, 2026. Strome Group, Inc., Strome Investment Management, LP and Strome Mezzanine Fund II, LP each report 3,650,000 shares, or 6.6%, with shared voting and dispositive power. The filing lists numerous recent open-market sales by the Fund between July 6 and August 12, 2026 at prices generally between $0.49 and $0.69 per share, which are noted as not yet reflected in the reported aggregate ownership figures.
HeartBeam, Inc. reported no revenue for the quarter and six months ended June 30, 2026 and continues to operate at a loss while developing its ambulatory cardiac monitoring platform. Net loss was $5.0 million for the quarter and $9.7 million for the first half of 2026.
Cash and cash equivalents were $8.7 million as of June 30, 2026, up from $4.4 million at year-end, primarily from an underwritten equity offering that generated $11.5 million in gross proceeds (about $10.3 million net) plus at-the-market sales. Operating cash outflow was $7.0 million in the first half.
The company discloses that existing liquidity is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. It received FDA clearances in December 2024 and December 2025 for its 3D ECG telehealth products, is running pilot and ALIGN-ACS studies, and is pursuing a shift toward licensing its 3D ECG signal technology and limited commercial launches. During the quarter HeartBeam also recorded CEO and director departures and received a Nasdaq minimum bid-price deficiency notice with a compliance period through December 29, 2026.